2025年,全球新药王诞生。礼来的替尔泊肽以365.07亿美元销售,力压诺和诺德的司美格鲁肽361亿美元和辉瑞的K药316亿美元。在替尔泊肽实现强劲增长的背景下,市场将更多的焦点放在未来的口服GLP-1市场大战上,口服司美格鲁肽年初在美上市的处方量趋势已经给市场打了个样。纵览外资机构观点,大部分达成一致共识:礼来Orforglipron将比口服司美格鲁肽的销售峰值要大得多,预计...
Source Link2025年,全球新药王诞生。礼来的替尔泊肽以365.07亿美元销售,力压诺和诺德的司美格鲁肽361亿美元和辉瑞的K药316亿美元。在替尔泊肽实现强劲增长的背景下,市场将更多的焦点放在未来的口服GLP-1市场大战上,口服司美格鲁肽年初在美上市的处方量趋势已经给市场打了个样。纵览外资机构观点,大部分达成一致共识:礼来Orforglipron将比口服司美格鲁肽的销售峰值要大得多,预计...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.